Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
about
Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapyThe inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancerA model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degenerationGenetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancerROR1 expression correlated with poor clinical outcome in human ovarian cancerEMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancerLow expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosisGenome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease RecurrenceSTAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.Adenovirus type 12 E1B 55-kilodalton oncoprotein promotes p53-mediated apoptotic response of ovarian cancer to cisplatin.Myeloid differentiation factor 88 promotes cisplatin chemoresistance in ovarian cancer.Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.SNPs and taxane toxicity in breast cancer patients.LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives
P2860
Q28109453-17B3E09B-F62E-48C5-9A85-79363CC95334Q28540458-1CBE3A1A-14A8-47E8-9AA9-05B160AC9B69Q33112264-13DFBCA0-AFC6-4A3C-A40F-D988807FF162Q33422082-E60A1241-C5DA-4826-876A-33DE6703CBD2Q33942010-1158DE00-7A54-4243-AE57-E58D658EC17AQ34202046-964836FD-930A-401A-8018-9E1034B9D391Q34783507-BBBBE694-C7B0-4738-B64A-871929DEF1AAQ36712351-6DD78252-8A93-486E-A54C-97FE2CBC72F9Q36761363-C9533975-6C33-4EA2-82D3-9A23D9097FFDQ37684533-B0B6864B-FA2F-457F-AC97-D73D68620898Q38389964-2B348B07-9588-4A91-B0C7-50E6460DF2A5Q38799468-32B6C35D-F2FC-4662-A42B-5836ED67096AQ38893456-993E1D92-9E86-4C82-ABBE-1709722868A2Q38948577-BDFBEE5A-1EBF-44B0-A020-4B78BA20E22EQ39790653-7169B92C-B42C-4E89-890D-8636A7990A94Q46800256-15F81FDE-4AF6-4E77-B42F-730A6A76C9EDQ47813357-68BD0D79-C230-40E2-B825-586C5EC123CBQ53066089-A90F6038-D4F8-4911-B079-A22F4885D090Q57174233-F438D556-07AD-4179-B16F-A7B07EDD028E
P2860
Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
@en
Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
@nl
type
label
Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
@en
Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
@nl
prefLabel
Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
@en
Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
@nl
P1476
Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
@en
P2093
Sharon Marsh
P2860
P356
10.1111/IGC.0B013E3181C10513
P478
19 Suppl 2
P577
2009-12-01T00:00:00Z